These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23252617)

  • 1. Replaced platelet concentrates containing a new additive solution, M-sol: safety and efficacy for pediatric patients.
    Yanagisawa R; Shimodaira S; Kojima S; Nakasone N; Ishikawa S; Momose K; Honda T; Yoshikawa K; Saito S; Tanaka M; Nakazawa Y; Sakashita K; Shiohara M; Akino M; Hirayama J; Azuma H; Koike K
    Transfusion; 2013 Sep; 53(9):2053-60. PubMed ID: 23252617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of administration of platelet concentrates suspended in M-sol or BRS-A for pediatric patients.
    Kojima S; Yanagisawa R; Tanaka M; Nakazawa Y; Shimodaira S
    Transfusion; 2018 Dec; 58(12):2952-2958. PubMed ID: 30291756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of platelet concentrates suspended in bicarbonated Ringer's solution in children who had platelet transfusion reactions.
    Kobayashi J; Yanagisawa R; Ono T; Tatsuzawa Y; Tokutake Y; Kubota N; Hidaka E; Sakashita K; Kojima S; Shimodaira S; Nakamura T
    Vox Sang; 2018 Feb; 113(2):128-135. PubMed ID: 29067694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol).
    Azuma H; Hirayama J; Akino M; Miura R; Kiyama Y; Imai K; Kasai M; Koizumi K; Kakinoki Y; Makiguchi Y; Kubo K; Atsuta Y; Fujihara M; Homma C; Yamamoto S; Kato T; Ikeda H
    Transfusion; 2009 Feb; 49(2):214-8. PubMed ID: 18798806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated exposure rather than the total volume of transfused components may influence the incidence of allergic transfusion reactions.
    Kato H; Nakayama T; Uruma M; Okuyama Y; Handa M; Tomiyama Y; Shimodaira S; Takamoto S
    Transfusion; 2015 Nov; 55(11):2576-81. PubMed ID: 26095126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of acute transfusion reactions to platelets in hospitalized pediatric patients based on the US hemovigilance reporting system.
    Li N; Williams L; Zhou Z; Wu Y
    Transfusion; 2014 Jun; 54(6):1666-72. PubMed ID: 24410992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of a new platelet pooling system for platelet concentrates led to a higher corrected count increment after transfusion: a comparative observational study of platelet concentrates before and after implementation.
    Dijkstra-Tiekstra MJ; van de Watering LM; Rondeel JM; Slomp J; de Wildt-Eggen J
    Transfus Med; 2014 Apr; 24(2):99-104. PubMed ID: 24506143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of factors associated with allergic transfusion reaction due to platelet transfusion and the efficacy of platelets resuspended in BRS-A in adult patients.
    Yamanaka M; Yanagisawa R; Kojima S; Nakazawa H; Shimodaira S
    Transfusion; 2019 Nov; 59(11):3405-3412. PubMed ID: 31532542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
    Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
    Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing adverse reactions in pediatric transfusions using washed platelet concentrate.
    Yanagisawa R
    Pediatr Int; 2021 Apr; 63(4):391-403. PubMed ID: 33290634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of donor- and recipient-associated factors to allergic transfusion reactions to platelets.
    Zheng Y; Pei D; Sweat L; Ryan M; Mestemacher MA; Gann M; Cheng C; Geiger TL
    Transfusion; 2021 Mar; 61(3):744-753. PubMed ID: 33314235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5CPD Erythro-Sol opti system.
    Högman CF; Eriksson L; Wallvik J; Payrat JM
    Vox Sang; 1997; 73(4):212-9. PubMed ID: 9407638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME).
    Tobian AA; Fuller AK; Uglik K; Tisch DJ; Borge PD; Benjamin RJ; Ness PM; King KE
    Transfusion; 2014 Jun; 54(6):1523-9; quiz 1522. PubMed ID: 24251374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Introduction of platelet additive solution in platelet concentrates: towards a decrease of blood transfusion reactions].
    Rebibo D; Simonet M; Hauser L
    Transfus Clin Biol; 2008 Nov; 15(5):289-93. PubMed ID: 18930424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors related to allergic transfusion reactions and febrile non-haemolytic transfusion reactions in children.
    Yanagisawa R; Shimodaira S; Sakashita K; Hidaka Y; Kojima S; Nishijima F; Hidaka E; Shiohara M; Nakamura T
    Vox Sang; 2016 May; 110(4):376-84. PubMed ID: 26808840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.
    Schlenke P; Hagenah W; Irsch J; Sundin D; Corash L; Lin L; Kirchner H; Wagner T
    Ann Hematol; 2011 Dec; 90(12):1457-65. PubMed ID: 21503644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion.
    Rasonglès P; Angelini-Tibert MF; Simon P; Currie C; Isola H; Kientz D; Slaedts M; Jacquet M; Sundin D; Lin L; Corash L; Cazenave JP
    Transfusion; 2009 Jun; 49(6):1083-91. PubMed ID: 19309473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction.
    Tobian AA; Savage WJ; Tisch DJ; Thoman S; King KE; Ness PM
    Transfusion; 2011 Aug; 51(8):1676-83. PubMed ID: 21214585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions.
    Hamzeh-Cognasse H; Damien P; Nguyen KA; Arthaud CA; Eyraud MA; Chavarin P; Absi L; Osselaer JC; Pozzetto B; Cognasse F; Garraud O
    Transfusion; 2014 Mar; 54(3):613-25. PubMed ID: 23944651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of platelet additive solution-E stored platelet concentrates.
    Spelmink SE; Jager ST; van de Watering L; van der Meer PF; van Gammeren AJ; Wiersum-Osselton JC; Klei TRL; Kerkhoffs JH;
    Transfusion; 2023 Dec; 63(12):2273-2280. PubMed ID: 37909172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.